Señales en vivo de 4547.T | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 00:04):

Stats
Volumen de hoy	20 500.00
Volumen promedio	92 366.00
Capitalización de mercado	161.36B
EPS	¥0 ( 2024-01-30 )
Próxima fecha de ganancias	( ¥110.76 ) 2024-05-06
Last Dividend	¥40.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.61
ATR14	¥3.84 (0.11%)

Volumen Correlación

Largo: -0.19 (neutral)

Corto: -0.27 (neutral)

Signal:(61.956) Neutral

Kissei Pharmaceutical Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kissei Pharmaceutical Correlación - Moneda/Commodity

0.28
( neutral )

-0.46
( neutral )

-0.71
( moderate negative )

-0.41
( neutral )

-0.24
( neutral )

Kissei Pharmaceutical Finanzas

Annual	2022
Ingresos:	¥67.49B
Beneficio Bruto:	¥32.38B (47.97 %)
EPS:	¥228.30

FY	2022
Ingresos:	¥67.49B
Beneficio Bruto:	¥32.38B (47.97 %)
EPS:	¥228.30

FY	2022
Ingresos:	¥65.38B
Beneficio Bruto:	¥31.24B (47.78 %)
EPS:	¥280.20

FY	2021
Ingresos:	¥69.04B
Beneficio Bruto:	¥32.72B (47.39 %)
EPS:	¥113.25

Financial Reports:

No articles found.

Kissei Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥40.00 (N/A)	¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Kissei Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.36 - Stable (12.73%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.00	2001-03-27
Last Dividend	¥40.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥794.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.68	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.36
Div. Directional Score	7.40	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.68

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8367.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7751.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
6929.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
6292.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
5015.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
4216.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3431.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
2531.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
9450.T	Ex Dividend Knight	2023-12-28	Annually	0.00%
8093.T	Ex Dividend Junior	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.165	1.500	6.69	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0534	1.200	8.22	9.86	[0 - 0.3]
returnOnEquityTTM	0.0620	1.500	-0.422	-0.634	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.93	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.22	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.155	1.500	4.69	7.04	[0.2 - 2]
debtRatioTTM	0.00608	-1.500	9.90	-10.00	[0 - 0.6]
interestCoverageTTM	141.28	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00707	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0345	1.000	-1.310	-1.310	[0.1 - 0.6]
cashFlowToDebtRatioTTM	6.04	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.323	0.800	-1.182	-0.946	[0.5 - 2]
Total Score				10.43

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.21	1.000	8.77	0	[1 - 100]
returnOnEquityTTM	0.0620	2.50	-0.272	-0.634	[0.1 - 1.5]
freeCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.29	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	186.97	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0896	1.500	-2.74	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.114	1.000	9.65	0	[0.1 - 0.5]
Total Score				4.36

Kissei Pharmaceutical

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.